The objective of the BioMILD study is to evaluate the efficacy of a CT scan plus plasma microRNA profiling as the initial screening test for the detection of lung cancer in heavy smokers.
Previously, the MILD trial by the same investigators showed the benefits of prolonging the screening period, and now they hypothesize that microRNA profiling in the first instance will lead to a reduction in the number of false-positive cases.
Ugo Pastorino outlines the study and it's key findings explains that the study demonstrated that the screening test can improve the results by separating individuals with different risk of lung cancer at the same exposure and age (3:09):
The BioMILD results were presented at WCLC 2019:
Title: Blood microRNA and LDCT reduce unnecessary LDCT repeats in lung cancer screening: Results of prospective BioMILD trial
Presenter: Ugo Pastorino, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Monday, September 9: 08:35–08:45 (Abstract PL02.04)